High-grade B-cell Lymphoma with Myc Bcl2 and Bcl6 Rearrangements
📧 Sign up to get email alerts when something new happens for High-grade B-cell Lymphoma with Myc Bcl2 and Bcl6 Rearrangements.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports ongoing Phase 1/2 testing of the combination epcoritamab plus ibrutinib for relapsed or refractory aggres…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma [Phase 2]
Phase 2 trial update on zanubrutinib combined with CAR T-cell therapy for recurrent or refractory aggressive B-cell non-Hodgkin lymphomas an…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial evaluating Dose Adjusted EPOCH combined with either ofatumumab or rituximab in newly diagnosed or relapsed/refractory Burkitt …